TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05019833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signals collection
Description: A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
Study: NCT06129240

Intervention type: COMBINATION_PRODUCT
Intervention: LIQ861
Description: trepostinil inhalation powder
Study: NCT06210503

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapcelar group nerve block
Description: In the supine position, a high-frequency linear sensor is placed in the anterior superior iliac spine and then aligned with the ramus of the pubis by rotating the probe counterclockwise approximately 45 degrees. The iliopsoas muscle and tendon, femoral artery, and pectineus muscle were observed in this view.The iliopsoas muscle and its tendon are visualized, as well as the vascular and nerve bundle: femoral artery, vein, and nerve. The needle is inserted laterally to medially in a planar approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the ramus pubis posteriorly. After negative aspiration, local anesthetic will be gradually injected aspirating every 3 mL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: In the supine position, a high-frequency linear sensor is placed in the inguinal fold. Scan starting lateral to the femoral artery and the nerve in the inguinal crease to identify the sartorius muscle, tracing the muscle to its origin to the anterior superior iliac spine. A shadow of the iliac crest bone and iliacus muscle will be visible, with the end point of injection being deep in the fascia iliaca and above the iliacus muscle at the lateral aspect of the iliacus muscle. After negative aspiration, local anesthetic will be gradually injected under the fascial plane, aspirating every 3 mL.
Study: NCT06666010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX010-Assisted Therapy
Description: The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEX010(01)
Description: The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Study: NCT06664866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EchoNet-LVH Assessment
Description: The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.
Study: NCT06665035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.
Study: NCT05326763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 50%
Description: The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
Study: NCT06665035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injection.
Study: NCT04865211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Use of liposomal bupivicaine as intraoperative local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Use of bupivicaine as intraoperative local anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of saline as placebo for local anesthesia
Study: NCT06665035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injection.
Study: NCT06666881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT only
Description: After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times a week and total 24-36 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT & Record of physical activities at home.
Description: After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times in a week and total 24-36 times. And do the recording of physical activities at home.
Study: NCT06666153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV immunological agent
Description: 27 participants with will be enrolled in the study and divided into three groups, including EBV-LPD (Adults group), EBV-LPD (Children group) and PTLD (Adults group） each with 9 people.The participants will be divided into three different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^5, the medium dose is 2.0×10\^6 and the high dose is 5.0×10\^6 for children and low dose is 5.0×10\^6, the medium dose is 2.0×10\^7 and the high dose is 5.0×10\^7 for adults. Only one dose will be administered to each participant with EBV immunological agent combined with Toripalimab 240mg.
Study: NCT06160739

Intervention type: DRUG
Intervention: Sirolimus 1Mg Oral Tablet
Description: patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug

Intervention type: DRUG
Intervention: Sirolimus 1Mg Oral Tablet
Description: patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug
Study: NCT05507658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Oxaliplatin and Capecitabine
Description: Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles.
Study: NCT05838924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHYSICAL ACTIVITY + VIRTUAL REALITY
Description: The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL ACTIVITY
Description: The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually.
Study: NCT05363657

Intervention type: PROCEDURE
Intervention: Partial Nephrectomy (PN)
Description: Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.

Intervention type: PROCEDURE
Intervention: Radical Nephrectomy (RN)
Description: Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.

Intervention type: PROCEDURE
Intervention: Ablation therapy (AT)
Description: The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.

Intervention type: DIAGNOSTIC_TEST
Intervention: Active Surveillance (AS)
Description: Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
Study: NCT06394765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Mapping
Description: Participants in the Mindful Mapping condition will receive a 5-minute, therapist-guided mindfulness intervention for chronic pain. During this training they will learn the 30-second Mindful Mapping technique, which they will be instructed to use each time they experience a painful sensation over the next 2 weeks. The Mindful Mapping technique consists of focusing on five basic characteristics (shape, weight, density, temperature, movement) of the most intense sensation in the body as it emerges in the present moment while remaining equanimous, i.e., preventing the learned reaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Serial Sevens
Description: Participants in the control condition will receive a 5-minute, therapist-guided serial sevens intervention for chronic pain. During this training, participants will be instructed that each time they experience pain, they will count backwards in their heads by 7 from 100 for 30 second.
Study: NCT04402658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Description: Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately \~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
Study: NCT05737433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-rencofilstat 225mg
Description: radio-labelled 225mg oral dose of rencofilstat
Study: NCT06668532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital toolkit
Description: Access to the Flourish app and instruction to use at least twice a week for 6 weeks.
Study: NCT05967182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)
Study: NCT06668532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National mental health resources
Description: Access to national mental health resources from Mental Health America, which can be found here: https://mhanational.org/ten-tools. Participants will receive one resource each week for 6 weeks and each time, will be asked to reflect on how the information can be applied to their own lives.
Study: NCT05341323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine.
Description: Peritonsillar infiltration of ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: peritonsillar infiltration of Bupivacaine
Study: NCT06495541

Intervention type: DRUG
Group type: OTHER
Intervention: Pyrotinib
Description: Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
Study: NCT05108207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention software
Description: The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Implement a program of non-pharmacological interventions to prevent delirium
Description: Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement a program of non-pharmacological interventions to prevent delirium
Description: Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
Study: NCT06432660

Intervention type: OTHER
Intervention: Data collection
Description: Information about radiation therapy via eye plaque brachytherapy and follow up
Study: NCT05774548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-depth interviews (IDI)
Description: In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group discussion (FGD)
Description: Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
Study: NCT06643676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data
Description: Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis
Description: A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
Study: NCT06161012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lenses (TEST)
Description: Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lenses (TEST)
Description: Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses (CONTROL)
Description: DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses (CONTROL)
Description: DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
Study: NCT05970120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUVISION NAV Ultrasound Catheter
Description: Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
Study: NCT05733975

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Making Guide
Description: The tool will be used by parent(s) to help guide them in discussion with their infant's clinicians.
Study: NCT05958940

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Therapy
Description: In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Blocking Glasses
Description: Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
Study: NCT05522075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Abstinence Intervention
Description: Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Abstinence Intervention
Description: Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
Study: NCT04619420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: JNJ-63733657 low or high dose will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: JNJ-63733657 low or high dose will be administered by IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to JNJ-63733657 will be administered by IV infusion.